Health and Healthcare
Many Biotechs Barely On Life Support (BPAX, CEGE, EPIX, IDMI, LJPC, NRGN, NFLD, TPTX)
Published:
Last Updated:
We have run a watch list of companies under their own strategic review, and the number of biotech (or grouped with biotech) stocks under this description is just staggering. We published a full review of this over at BioHealthInvestor.com. The list includes Biosante Pharmaceuticals, Inc. (NASDAQ: BPAX), Cell Genesys, Inc. (NASDAQ: CEGE), EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), IDM Pharma, Inc. (NASDAQ: IDMI), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Neurogen Corporation (NASDAQ: NRGN), Northfield Laboratories Inc. (NASDAQ: NFLD) and TorreyPines Therapeutics, Inc. (NASDAQ: TPTX) are all under strategic reviews and their futures are probably questionable at best.
You can read that full report here at the BioHealthInvestor.com website.
Jon C. Ogg
May 13, 2009
Buffett Missed These Two…
Warren Buffett loves dividend stocks, and has stuffed Berkshire with some of his favorites.
But he overlooked two dividend legends that continue to print checks on a new level, they’re nowhere in his portfolio.
Unlock the two dividend legends Buffett missed in this new free report.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
